Matej Skorvanek1,2, Pablo Martinez-Martin3, Norbert Kovacs4,5, Mayela Rodriguez-Violante6, Jean-Christophe Corvol7, Pille Taba8, Klaus Seppi9, Oleg Levin10, Anette Schrag11, Thomas Foltynie12, Mario Alvarez-Sanchez13, Tomoko Arakaki14, Zsuzsanna Aschermann4, Iciar Aviles-Olmos12, Eve Benchetrit7, Charline Benoit7, Alberto Bergareche-Yarza15, Amin Cervantes-Arriaga16, Anabel Chade17, Florence Cormier7, Veronika Datieva10, David A Gallagher18, Nelida Garretto14, Zuzana Gdovinova1,2, Oscar Gershanik17, Milan Grofik19, Vladimir Han1,2, Jing Huang20, Liis Kadastik-Eerme8, Monica M Kurtis21, Graziella Mangone7, Juan Carlos Martinez-Castrillo22, Amelia Mendoza-Rodriguez23, Michal Minar24, Henry P Moore25, Mari Muldmaa26, Christoph Mueller9, Bernadette Pinter9, Werner Poewe9, Karin Rallmann8, Eva Reiter9, Carmen Rodriguez-Blazquez3, Carlos Singer25, Barbara C Tilley20, Peter Valkovic24, Christopher G Goetz27, Glenn T Stebbins27. 1. Department of Neurology P. J. Safarik University Kosice Slovak Republic. 2. Department of Neurology University Hospital L. Pasteur Kosice Slovak Republic. 3. National Center of Epidemiology and Centro de Investigación Biomedica en Red de Enfermedades Neurodegenerativas (CIBERNED) Carlos III Institute of Health Madrid Spain. 4. Department of Neurology University of Pécs Pécs Hungary. 5. MTA-PTE Clinical Neuroscience MR Research Group Pécs Hungary. 6. Movement Disorders Unit Instituto Nacional de Neurologia y Neurocirugia Mexico Distrito Federal Mexico. 7. Département des Maladies du Système Nerveux Sorbonne Universités Université Pierre et Marie Curie (UPMC) Paris 06; Institut National de la Santé et de la Recherche Médicale (INSERM) UMRS-1127 CIC-1422; CNRS UMR-7225; Assistance Publique-Hôpitaux de Paris (AP-HP); and Institut du Cerveau et de la Moelle Épinière (ICM) Hôpital Pitié-Salpêtrière Paris France. 8. Department of Neurology and Neurosurgery University of Tartu Tartu Estonia. 9. Department of Neurology Medical University of Innsbruck Innsbruck Austria. 10. Department of Neurology Russian Medical Academy of Postgraduate Education Moscow Russia. 11. Department of Clinical Neuroscience University College London Institute of Neurology London UK. 12. Sobell Department of Motor Neuroscience University College London Institute of Neurology London UK. 13. Department of Movement Disorders and Neurodegeneration Centro Internacional de Restauración Neurológica (CIREN) La Habana Cuba. 14. Department of Neurology Hospital Ramos Mejia Buenos Aires Argentina. 15. Department of Neurology Donostia Hospital Biodonostia Institute and Centro de Investigación Biomedica en Red de Enfermedades Neurodegenerativas (CIBERNED) San Sebastian Spain. 16. Clinical Neurodegenerative Diseases Research Unit Instituto Nacional de Neurología y Neurocirugía Mexico City Mexico. 17. Movement Disorders Unit Institute of Neurosciences Favaloro University Institute of Cognitive Neurology Buenos Aires Argentina. 18. Barts Health National Health Service Trust The Royal London Hospital London UK. 19. Department of Neurology Comenius University Martin Slovak Republic. 20. Division of Biostatistics University of Texas School of Public Health at Houston Houston Texas USA. 21. Movement Disorders Program Department of Neurology Hospital Ruber Internacional Madrid Spain. 22. Movement Disorders Unit Department of Neurology Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS) Madrid Spain. 23. Department of Neurology Complejo Asistencial de Segovia Segovia Spain. 24. Second Department of Neurology Faculty of Medicine Comenius University Bratislava Slovak Republic. 25. Department of Neurology University of Miami Miami Florida USA. 26. Department of Neurology North Estonian Medical Center Tallinn Estonia. 27. Department of Neurological Sciences Rush University Medical Center Chicago Illinois USA.
Abstract
BACKGROUND: The Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is a newly developed tool to assess Parkinson's disease (PD). Changes in scores on the scale over the course of PD, including increasing disease duration and Hoehn and Yahr (HY) stages, have not been described. The objectives of this study were to analyze MDS-UPDRS scores on Parts I through IV and their differences based on HY stage and disease duration in a large cohort of patients with PD. METHODS: For this cross-sectional study, demographic data and MDS-UPDRS scores were collected, including HY stage. Subscores on MDS-UPDRS Parts I through IV were analyzed using 1-way analyses of variance for each HY stage and in 5-year increments of disease duration. Part III (motor assessment) scores were analyzed separately for on and off states. RESULTS: The mean age of the 3206 patients was 65.8 ± 10.6 years, 53.3% were men, the mean disease duration was 11.5 ± 4.6 years, and the median HY stage was 2 (range, 0-5); 2156 patients were examined in an on state and 987 were examined in an off state. Scores for all MDS-UPDRS parts increased significantly through HY stages 1 through 5, with an average increase of 3.8, 7.7, 14.6, and 2.0 points consecutively for parts I through IV, respectively. For the 5-year increments of disease duration, MDS-UPDRS subscores increased by an average of 1.6, 3.3, 4.2, and 1.4 points consecutively for parts I through IV, respectively. This increase was significant only during the first 15 years of disease for all 4 parts, including part III scores evaluated in both on and off states. CONCLUSIONS: MDS-UPDRS scores for all 4 parts increase significantly with every HY stage and also with 5-year increments of disease duration in the first 15 years of the disease.
BACKGROUND: The Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is a newly developed tool to assess Parkinson's disease (PD). Changes in scores on the scale over the course of PD, including increasing disease duration and Hoehn and Yahr (HY) stages, have not been described. The objectives of this study were to analyze MDS-UPDRS scores on Parts I through IV and their differences based on HY stage and disease duration in a large cohort of patients with PD. METHODS: For this cross-sectional study, demographic data and MDS-UPDRS scores were collected, including HY stage. Subscores on MDS-UPDRS Parts I through IV were analyzed using 1-way analyses of variance for each HY stage and in 5-year increments of disease duration. Part III (motor assessment) scores were analyzed separately for on and off states. RESULTS: The mean age of the 3206 patients was 65.8 ± 10.6 years, 53.3% were men, the mean disease duration was 11.5 ± 4.6 years, and the median HY stage was 2 (range, 0-5); 2156 patients were examined in an on state and 987 were examined in an off state. Scores for all MDS-UPDRS parts increased significantly through HY stages 1 through 5, with an average increase of 3.8, 7.7, 14.6, and 2.0 points consecutively for parts I through IV, respectively. For the 5-year increments of disease duration, MDS-UPDRS subscores increased by an average of 1.6, 3.3, 4.2, and 1.4 points consecutively for parts I through IV, respectively. This increase was significant only during the first 15 years of disease for all 4 parts, including part III scores evaluated in both on and off states. CONCLUSIONS: MDS-UPDRS scores for all 4 parts increase significantly with every HY stage and also with 5-year increments of disease duration in the first 15 years of the disease.
Entities:
Keywords:
Hoehn and Yahr; Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS‐UPDRS); Parkinson's disease; disease duration; scale
Authors: Christopher G Goetz; Werner Poewe; Olivier Rascol; Cristina Sampaio; Glenn T Stebbins; Carl Counsell; Nir Giladi; Robert G Holloway; Charity G Moore; Gregor K Wenning; Melvin D Yahr; Lisa Seidl Journal: Mov Disord Date: 2004-09 Impact factor: 10.338
Authors: K Ray Chaudhuri; A Sauerbier; J M Rojo; K Sethi; A H V Schapira; R G Brown; A Antonini; F Stocchi; P Odin; K Bhattacharya; Y Tsuboi; K Abe; A Rizos; Carmen Rodriguez-Blazquez; P Martinez-Martin Journal: Parkinsonism Relat Disord Date: 2015-01-05 Impact factor: 4.891
Authors: Pablo Martinez-Martin; Carmen Rodriguez-Blazquez; Mario Alvarez-Sanchez; Tomoko Arakaki; Alberto Bergareche-Yarza; Anabel Chade; Nelida Garretto; Oscar Gershanik; Monica M Kurtis; Juan Carlos Martinez-Castrillo; Amelia Mendoza-Rodriguez; Henry P Moore; Mayela Rodriguez-Violante; Carlos Singer; Barbara C Tilley; Jing Huang; Glenn T Stebbins; Christopher G Goetz Journal: J Neurol Date: 2012-08-05 Impact factor: 4.849
Authors: Christopher G Goetz; Barbara C Tilley; Stephanie R Shaftman; Glenn T Stebbins; Stanley Fahn; Pablo Martinez-Martin; Werner Poewe; Cristina Sampaio; Matthew B Stern; Richard Dodel; Bruno Dubois; Robert Holloway; Joseph Jankovic; Jaime Kulisevsky; Anthony E Lang; Andrew Lees; Sue Leurgans; Peter A LeWitt; David Nyenhuis; C Warren Olanow; Olivier Rascol; Anette Schrag; Jeanne A Teresi; Jacobus J van Hilten; Nancy LaPelle Journal: Mov Disord Date: 2008-11-15 Impact factor: 10.338
Authors: Manuel Montero-Odasso; Nathalie van der Velde; Finbarr C Martin; Mirko Petrovic; Maw Pin Tan; Jesper Ryg; Sara Aguilar-Navarro; Neil B Alexander; Clemens Becker; Hubert Blain; Robbie Bourke; Ian D Cameron; Richard Camicioli; Lindy Clemson; Jacqueline Close; Kim Delbaere; Leilei Duan; Gustavo Duque; Suzanne M Dyer; Ellen Freiberger; David A Ganz; Fernando Gómez; Jeffrey M Hausdorff; David B Hogan; Susan M W Hunter; Jose R Jauregui; Nellie Kamkar; Rose-Anne Kenny; Sarah E Lamb; Nancy K Latham; Lewis A Lipsitz; Teresa Liu-Ambrose; Pip Logan; Stephen R Lord; Louise Mallet; David Marsh; Koen Milisen; Rogelio Moctezuma-Gallegos; Meg E Morris; Alice Nieuwboer; Monica R Perracini; Frederico Pieruccini-Faria; Alison Pighills; Catherine Said; Ervin Sejdic; Catherine Sherrington; Dawn A Skelton; Sabestina Dsouza; Mark Speechley; Susan Stark; Chris Todd; Bruce R Troen; Tischa van der Cammen; Joe Verghese; Ellen Vlaeyen; Jennifer A Watt; Tahir Masud Journal: Age Ageing Date: 2022-09-02 Impact factor: 12.782
Authors: Brenna A Cholerton; Kathleen L Poston; Laurice Yang; Liana S Rosenthal; Ted M Dawson; Alexander Pantelyat; Karen L Edwards; Lu Tian; Joseph F Quinn; Kathryn A Chung; Amie L Hiller; Shu-Ching Hu; Thomas J Montine; Cyrus P Zabetian Journal: J Clin Exp Neuropsychol Date: 2021-08-06 Impact factor: 2.283